カテゴリー： Transparency Market Research, 世界, 医療/バイオ

マルチパラメーターin vitro心毒性検査の世界市場（2022～2031）：アッセイ種類別

◆英語タイトル：Multiparametric In-vitro Cardiotoxicity Testing Market (Type of Assay: Calcium Transient Assay, Cardiac Marker Detection, hERG Assay, Multi-ion Channel Assay, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transparency Market Researchが発行した調査報告書（TMR23AP144）◆商品コード：TMR23AP144
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2023年1月6日
◆ページ数：167
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の本調査レポートでは、マルチパラメーターin vitro心毒性検査の世界市場について総合的に分析し、今後の市場動向を予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、アッセイ種類別（カルシウムトランジェントアッセイ、心臓マーカー検出、hERGアッセイ、マルチイオンチャネルアッセイ、その他）分析、エンドユーザー別（CRO、製薬＆バイオテクノロジー企業、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他）分析、競争状況などの項目が整理されています。また、本書内には、Creative Bioarray、Agilent Technologies, Inc.、Hemogenix Inc.、Merck KGaA、Molecular Devices, LLC.、Miltenyi Biotec、FUJIFILM Cellular Dynamics、Enzo Life Sciences, Inc.、Axol Bioscience Ltd.、emka TECHNOLOGIES、Eurofins Discovery、Stemina Biomarker Discovery, Inc.、Evotecなどの企業情報が含まれています。
・序論
・仮定＆調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界のマルチパラメーターin vitro心毒性検査市場規模：アッセイ種類別
- カルシウムトランジェントアッセイの市場規模
- 心臓マーカー検出の市場規模
- hERGアッセイの市場規模
- マルチイオンチャネルアッセイの市場規模
- その他アッセイ種類の市場規模
・世界のマルチパラメーターin vitro心毒性検査市場規模：エンドユーザー別
- CROにおける市場規模
- 製薬＆バイオテクノロジー企業における市場規模
- その他エンドユーザーにおける市場規模
・世界のマルチパラメーターin vitro心毒性検査市場規模：地域別
- 北米のマルチパラメーターin vitro心毒性検査市場規模
- ヨーロッパのマルチパラメーターin vitro心毒性検査市場規模
- アジア太平洋のマルチパラメーターin vitro心毒性検査市場規模
- その他地域のマルチパラメーターin vitro心毒性検査市場規模
・競争状況

Multiparametric In-vitro Cardiotoxicity Testing Market – Scope of Report
TMR’s report on the global multiparametric in-vitro cardiotoxicity testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global multiparametric in-vitro cardiotoxicity testing market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global multiparametric in-vitro cardiotoxicity testing market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the multiparametric in-vitro cardiotoxicity testing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global multiparametric in-vitro cardiotoxicity testing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global multiparametric in-vitro cardiotoxicity testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global multiparametric in-vitro cardiotoxicity testing market.

The report delves into the competitive landscape of the global multiparametric in-vitro cardiotoxicity testing market. Key players operating in the global multiparametric in-vitro cardiotoxicity testing market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global multiparametric in-vitro cardiotoxicity testing market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market multiparametric in-vitro cardiotoxicity testing.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Multiparametric In-vitro Cardiotoxicity Testing Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, 2017 – 2031
        4.4.1. Market Revenue Projection (US$ Mn)
5. Key Insights
    5.1. Key Industry Developments
    5.2. Key Product/Brand Analysis
    5.3. Emerging Technologies and Platforms for Cardiotoxicity Testing
    5.4. Overview of In-vitro Cardiac Electrophysiology Platforms for Toxicology Assessment
    5.5. Overview of Multiparametric In-vitro Toxicology Assessment
    5.6. COVID-19 Impact Analysis
6. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By Type of Assay
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast By Type of Assay, 2017 – 2031
        6.3.1. Calcium Transient Assay
        6.3.2. Cardiac Marker Detection
        6.3.3. hERG Assay
        6.3.4. Multi-ion Channel Assay
        6.3.5. Others
    6.4. Market Attractiveness By Type of Assay
7. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By End-user
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast By End-user, 2017 – 2031
        7.3.1. Contract Research Organizations (CROs)
        7.3.2. Pharmaceutical and Biotech Companies
        7.3.3. Others
    7.4. Market Attractiveness By End-user
8. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By Region
    8.1. Key Findings
    8.2. Market Value Forecast By Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Rest of the World
    8.3. Market Attractiveness By Country/Region
9. North America Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast By Type of Assay, 2017 – 2031
        9.2.1. Calcium Transient Assay
        9.2.2. Cardiac Marker Detection
        9.2.3. hERG Assay
        9.2.4. Multi-ion Channel Assay
        9.2.5. Others
    9.3. Market Value Forecast By End-user, 2017 – 2031
        9.3.1. Contract Research Organizations (CROs)
        9.3.2. Pharmaceutical and Biotech Companies
        9.3.3. Others
    9.4. Market Value Forecast By Country, 2017 – 2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Type of Assay
        9.5.2. By End-user
        9.5.3. By Country
10. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast By Type of Assay, 2017 – 2031
        10.2.1. Calcium Transient Assay
        10.2.2. Cardiac Marker Detection
        10.2.3. hERG Assay
        10.2.4. Multi-ion Channel Assay
        10.2.5. Others
    10.3. Market Value Forecast By End-user, 2017 – 2031
        10.3.1. Contract Research Organizations (CROs)
        10.3.2. Pharmaceutical and Biotech Companies
        10.3.3. Others
    10.4. Market Value Forecast By Country/Sub-region, 2017 – 2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Type of Assay
        10.5.2. By End-user
        10.5.3. By Country/Sub-region
11. Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast By Type of Assay, 2017 – 2031
        11.2.1. Calcium Transient Assay
        11.2.2. Cardiac Marker Detection
        11.2.3. hERG Assay
        11.2.4. Multi-ion Channel Assay
        11.2.5. Others
    11.3. Market Value Forecast By End-user, 2017 – 2031
        11.3.1. Contract Research Organizations (CROs)
        11.3.2. Pharmaceutical and Biotech Companies
        11.3.3. Others
    11.4. Market Value Forecast By Country/Sub-region, 2017 – 2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Type of Assay
        11.5.2. By End-user
        11.5.3. By Country/Sub-region
12. Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Type of Assay, 2017 – 2031
        12.2.1. Calcium Transient Assay
        12.2.2. Cardiac Marker Detection
        12.2.3. hERG Assay
        12.2.4. Multi-ion Channel Assay
        12.2.5. Others
    12.3. Market Value Forecast By End-user, 2017 – 2031
        12.3.1. Contract Research Organizations (CROs)
        12.3.2. Pharmaceutical and Biotech Companies
        12.3.3. Others
    12.4. Market Attractiveness Analysis
        12.4.1. By Type of Assay
        12.4.2. By End-user
13. Competition Landscape
    13.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    13.2. Market Share Analysis By Company (2021)
    13.3. Company Profiles
        13.3.1. Creative Bioarray
            13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.1.2. Product Portfolio
            13.3.1.3. SWOT Analysis
            13.3.1.4. Strategic Overview
        13.3.2. Agilent Technologies, Inc.
            13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.2.2. Product Portfolio
            13.3.2.3. SWOT Analysis
            13.3.2.4. Strategic Overview
        13.3.3. Hemogenix Inc.
            13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.3.2. Product Portfolio
            13.3.3.3. SWOT Analysis
            13.3.3.4. Strategic Overview
        13.3.4. Merck KGaA
            13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.4.2. Product Portfolio
            13.3.4.3. SWOT Analysis
            13.3.4.4. Strategic Overview
        13.3.5. Molecular Devices, LLC
            13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.5.2. Product Portfolio
            13.3.5.3. SWOT Analysis
            13.3.5.4. Strategic Overview
        13.3.6. Evotec
            13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.6.2. Product Portfolio
            13.3.6.3. SWOT Analysis
            13.3.6.4. Strategic Overview
        13.3.7. Miltenyi Biotec
            13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.7.2. Product Portfolio
            13.3.7.3. SWOT Analysis
            13.3.7.4. Strategic Overview
        13.3.8. FUJIFILM Cellular Dynamics
            13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.8.2. Product Portfolio
            13.3.8.3. SWOT Analysis
            13.3.8.4. Strategic Overview
        13.3.9. Enzo Life Sciences, Inc.
            13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.9.2. Product Portfolio
            13.3.9.3. SWOT Analysis
            13.3.9.4. Strategic Overview
        13.3.10. Axol Bioscience Ltd.
            13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.10.2. Product Portfolio
            13.3.10.3. SWOT Analysis
            13.3.10.4. Strategic Overview
        13.3.11. Stemina Biomarker Discovery, Inc.
            13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.11.2. Product Portfolio
            13.3.11.3. SWOT Analysis
            13.3.11.4. Strategic Overview
        13.3.12. emka TECHNOLOGIES
            13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.12.2. Product Portfolio
            13.3.12.3. SWOT Analysis
            13.3.12.4. Strategic Overview
        13.3.13. Eurofins Discovery
            13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            13.3.13.2. Product Portfolio
            13.3.13.3. SWOT Analysis
            13.3.13.4. Strategic Overview

List of Tables

Table 01: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

Table 02: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 03: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 05: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

Table 06: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 07: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 08: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

Table 09: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 10: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

Table 12: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

Table 14: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ マルチパラメーターin vitro心毒性検査の世界市場（2022～2031）：アッセイ種類別(Multiparametric In-vitro Cardiotoxicity Testing Market (Type of Assay: Calcium Transient Assay, Cardiac Marker Detection, hERG Assay, Multi-ion Channel Assay, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 便中カルプロテクチン検査の世界市場2023～2031：患者種類別、アッセイ種類別
  • 加熱式加湿器の世界市場（2022～2031）：種類別
  • 血行動態モニタリングシステムの世界市場（2022～2031）：製品別、技術種類別
  • 乳児用酸素フードの世界市場（2022～2031）：材料別、用途別

    • ◆H&Iグローバルリサーチのお客様（例）◆